Awarded grant by The Michael J. Fox Foundation for Parkinson’s Research
Saniona, a leading biotech company in the field of ion channels, today announced that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded Saniona a research grant of up to USD 590,700 (approximately SEK 5.1 million) to develop small-molecule modulators of nicotine receptors belonging to a subtype named alpha-6 and evaluate the feasibility of using these drug candidates for the treatment of Parkinson’s disease.
“We are very proud that The Michael J. Fox Foundation for Parkinson’s Research supports the development of our technology and our work with MJFF illustrates our commitment to delivering cutting-edge research towards new medications for severe neurological disorders,” says Jørgen Drejer, CEO of Saniona.
The Saniona research team is the first to present small molecules that specifically facilitate the function of nicotinic alpha-6 receptors, which mediate dopamine signalling. Earlier research has shown nicotinic alpha-6 modulators may offer a novel approach to protect dopamine neurons from degeneration seen in Parkinson’s disease.
“The development of therapies to address unmet needs of people with Parkinson’s disease is a top priority of The Michael J. Fox Foundation, and nicotinic alpha-6 modulators present a promising novel approach,” says Marco Baptista, PhD, MJFF director of research programs.
Saniona will apply the grant from MJFF to demonstrate relevant facilitation of dopamine neurons and to perform a chemical optimization of its nicotinic alpha-6 modulators in order to identify compounds suitable to demonstrate activity in relevant animal models. Once an optimal tool compound is generated, Saniona will conduct functional proof-of-principle studies and assess potential neuroprotective effects.
Should this project confirm a functional facilitation of dopamine release from relevant brain regions, the next steps would be to accelerate this program toward lead optimization to identify a therapeutic candidate to be advanced into pre-clinical development for the possible initiation of Phase 1 clinical trials.
“If this research and subsequently preclinical development prove successful, we hope to deliver a potential disease modifying therapy that slow or stop the dopamine neuron loss seen in Parkinson’s disease,” says Jørgen Drejer, CEO of Saniona.
For more information, please contact
Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: firstname.lastname@example.org
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Upsher-Smith Laboratories, Inc. and Saniona’s Boston based spinout Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Idec Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at AktieTorget since April 2014 and has about 3,000 shareholders. The company’s share is traded under the ticker SANION. Read more at www.saniona.com.
About Parkinson’s disease
Parkinson’s disease is a chronic and progressive neurological disorder that is characterized by well-known motor symptoms including tremors, stiffness of limbs, slowness of movements, and difficulties with posture and balance. In addition to motor symptoms, many Parkinson’s disease patients experience non-motor symptoms, including sleep disorders, sensory symptoms, depression and gastrointestinal symptoms.
It is the second most common neurological disorder and more than five million people worldwide live with this disease. Parkinson’s disease is more common in people over 60 years of age, but the disease also afflicts people as young as in their late 20s. In healthy people, the motor system is regulated by nerve cells that communicate with each other using dopamine. In Parkinson’s disease, dopamine-producing cells in the brain degenerate, affecting the entire central nervous system. This causes an impairment of communication between the cells leading to the loss of control of movements. Current Parkinson’s treatments are only effective in managing symptoms of the disease. As the disease progresses and dopaminergic neurons continue to be lost, these drugs eventually become less effective at treating the symptoms.
About Nicotine alpha-6 modulators
Nicotinic alpha-6 receptors exhibit an extremely localized expression, mainly confined to dopamine neurons. In these neurons, they are expressed on the nerve endings innervating a brain region named striatum, where they are important mediators of local regulation of dopamine signalling by the signalling molecule acetylcholine. The Saniona research team is the first to present selective allosteric modulators of nicotinic alpha-6 receptors and has furthermore demonstrated that these modulators increase the receptor sensitivity for acetylcholine. The identified nicotinic alpha-6 modulators have the potential to strengthen acetylcholine-mediated dopamine release at the nerve endings in striatum and thereby offer a novel approach to protect and counteract degeneration of dopamine neurons in Parkinson’s disease patients.
About The Michael J. Fox Foundation for Parkinson’s Research
As the world’s largest non-profit funder of Parkinson’s research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $525 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson’s research, the Foundation forges ground-breaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson’s disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson’s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.